TreAtments and outComes in paTients With prImary CutAneous Lymphoma
NCT05518851 · Phase II · Beijing, Beijing Municipality, China
- Condition
- Lymphoma
- Disease stage
- Stage I-IV
- Phase
- Phase II
- Study type
- Targeted Therapy
- Age
- 18 Years and older
- Gender
- All
- Sponsor
- Peking University First Hospital
- Research institution
- Peking University First Hospital
- Facility
- Peking University Third Hospital
- Research center
- Peking University Third Hospital
Summary
In order to further improve the diagnosis and treatment level of primary cutaneous lymphoma in China, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for primary cutaneous lymphoma to systematically and effectively understand the current treatment status of patients with primary cutaneous lymphoma, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of primary cutaneous lymphoma and help patients with primary cutaneous lymphoma.
Detailed description
Primary cutaneous lymphomas (PCLs) are defined as non-Hodgkin lymphomas presenting in the skin with no evidence of extracutaneous disease at the time of diagnosis. Primary cutaneous lymphomas include a heterogeneous group of cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas (CBCLs). The different types of PCLs have highly characteristic clinical and histologic features, often a completely different clinical behavior and prognosis, and require a different type of treatment. Various studied in terms of the treatment and outcome of patients with different types of PCLs has been conducted in recent years. While the data of Chinese patients with PCLs are limited. Considering the different proportion of PCLs and limited treatment modalities in China, a nationwide multi-center prospective study is designed to summarize the current treatment status and outcome of patients.
Inclusion criteria
* Patients from the participatin medical centers that has passed the data review of the National Clinical Center for Skin and Immune Diseases. * Patients with a definitive pathological diagnosis of primary cutaneous lymphoma by skin biopsy.
Exclusion criteria
* Patients who fail to provide informed consent form. * Patients who cannot complete the questionnaire independently or under the guidance of investigators.
Primary outcomes
Type of significant therapies; Duration of significant therapies; Clinical response to significant therapies
Secondary outcomes
Overall survival (OS); Progression Free Survival (PFS); Disease Specific Survival (DSS)